Mayne Pharma Group Limited

Equities

MYX

AU000000MYX0

Pharmaceuticals

Market Closed - Australian S.E. 02:10:46 2024-06-13 am EDT 5-day change 1st Jan Change
4.48 AUD -6.28% Intraday chart for Mayne Pharma Group Limited -9.13% -27.15%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Swissmedic Grants Mayne Pharma Group Expanded Kapanol Dosage Approvals in Switzerland MT
Mayne Pharma Reiterates H2 FY24 Outlook in Wake of Change Healthcare Cyberattack MT
Mayne Pharma Group Limited's Equity Buyback announced on May 10, 2023 has expired with 3,828,461 shares, representing 4.59% for AUD 17.16 million. CI
Mayne Pharma Group Limited's Equity Buyback Plan Extended till November 29, 2024. CI
Mayne Pharma Group Limited announces an Increase in Equity Buyback. CI
Mayne Pharma Group's Nextstellis Oral Contraceptive Receives Two Additional US Patents MT
Mayne Pharma Group Swings to Loss in Fiscal H1 Despite Revenue Growth; Shares Jump 15% MT
Transcript : Mayne Pharma Group Limited, H1 2024 Earnings Call, Feb 26, 2024
Tranche Update on Mayne Pharma Group Limited's Equity Buyback Plan announced on May 10, 2023. CI
Mayne Pharma Group Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Mithra Pharmaceuticals Exits Stake in Mayne Pharma MT
An undisclosed buyer acquired a 5.06% stake in Mayne Pharma Group Limited from Mithra Pharmaceuticals SA for AUD 21 million CI
Transcript : Mayne Pharma Group Limited Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 07:30 AM
Mayne Pharma Group Limited Approves Election of Anne Lockwood CI
Transcript : Mayne Pharma Group Limited - Shareholder/Analyst Call
Mithra Pharmaceuticals Obtains US Patent for Contraceptive Pill MT
Mayne Pharma Gets Additional US Patent for Contraceptive MT
Mayne Pharma Gets Go-Ahead for Resignation of EY as Auditor MT
Transcript : Mayne Pharma Group Limited - Shareholder/Analyst Call
Mayne Pharma Acquires Dermatological Medication MT
Mayne Pharma Group Limited completed the acquisition of Assets Related To RHOFADE® (Oxymetazoline Hydrochloride) Cream 1% from EPI Health, LLC. CI
Mayne Pharma Group Limited agreed to acquire Assets Related To RHOFADE® (Oxymetazoline Hydrochloride) Cream 1% from EPI Health, LLC for $8 million. CI
Australian Shares Rebound Ahead of Central Bank Policy Meeting MT
Mayne Pharma Group Purchasing Global Rights to Topical Treatment RHOFADE MT
Transcript : Mayne Pharma Group Limited, 2023 Earnings Call, Aug 31, 2023
Chart Mayne Pharma Group Limited
More charts
Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused on commercializing novel pharmaceuticals. The Company also provides contract development and manufacturing services to clients worldwide. The Company’s segments include Women’s Health, Dermatology, and International. The Women’s Health segment distributes women’s health branded products in the United States. This segment includes NEXTSTELLIS, ANNOVERA, BIJUVA, IMVEXXY and branded pre-natal vitamins. The Dermatology segment distributes established dermatology products in the United States. The International segment is engaged in the manufacture and sale of branded and generic pharmaceutical products globally and the provision of contract development and manufacturing services to third party customers. The Company's products include ACTIKERALL Solution, ASTRIX Capsules and Tablets, MAGNOPLASM Paste and SPLINTEX Splinter Removal Gel, and ANNOVERA Vaginal Ring, among others.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.48 AUD
Average target price
6.89 AUD
Spread / Average Target
+53.79%
Consensus
  1. Stock Market
  2. Equities
  3. MYX Stock
  4. News Mayne Pharma Group Limited
  5. Mayne Pharma Gets Additional US Patent for Contraceptive